Clinical trials have demonstrated that SGLT2 inhibitors confer unexpected benefits beyond glycemic control, including a 38% reduction in the risk of major cardiovascular events, delayed progression of chronic kidney disease, a 35% decrease in hospitalization rates for heart failure, and a lower incidence of acute kidney injury [138,139]. The gene discussed is SLC5A2; the disease is chronic kidney disease.